Raising and narrowing 2024 guidance ranges: Adjusted EBITDA of $750 to $780 million and Adjusted Free Cash Flow of $265 to $285 million. Reaffirming 2025 guidance ranges: Adjusted EBITDA of $925 to $1 ...
3hon MSN
The National Hurricane Center is monitoring Potential Tropical Cyclone 19, which could impact Florida sometime next week | ...
PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...
and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings ...
In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a ...
Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...
The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback